Description
Cagrilintide is an amylin-analog in development as a treatment for individuals dealing with overweight and obesity. By replicating the effects of naturally occurring amylin, cagrilintide effectively curbs appetite and reduces food intake.
When used in tandem with semaglutide, a proven GLP-1 agonist that enhances satiety and slows down gastric emptying, the duo forms a potent therapeutic strategy designed to promote significant and long-lasting weight loss. This novel approach not only aids in achieving remarkable weight loss results but also helps maintain them, addressing a major challenge in obesity treatment and potentially transforming the therapeutic landscape with improved health outcomes for many.
Cagrilintide is still undergoing clinical trials and has not received FDA approval yet. The long-term effects of this drug is not yet fully known.
Book a consultation to speak to a provider about treatment options
